A group of 80 researchers say that a so-called ‘herd immunity’ approach to managing COVID-19 by allowing immunity to develop in low-risk populations is “a dangerous fallacy unsupported by the scientific evidence”.
Charles Knight, Professor of Cardiology at Queen Mary University of London and Chief Executive of St Bartholomew’s Hospital, has received an OBE for services to the NHS and people with heart disease in the Queen’s birthday honours.
Poor bone quality is linked to poor heart health
25 September 2020
New research by Queen Mary University of London and the University of Southampton’s Medical Research Council Lifecourse Epidemiology Unit (MRC LEU) has found associations between lower bone mineral density and worse cardiovascular health in both men and women.
Researcher awarded prestigious cardiology prize for MRI discovery
22 September 2020
Dr Nay Aung, an academic clinical lecturer at Queen Mary University of London, has been awarded the Royal Society of Medicine President’s prize for best cardiology PhD project.
Dr Robin. N. Poston from the Centre for Microvascular Research at the William Harvey Research Institute has recently published a new review paper concerning a potential treatment for COVID-19. The work he co-authored with Dr Paula Heister from University of Cambridge was included in the Journal of Pharmacological Research and Perspectives.
ROR2 blockade as a therapy for osteoarthritis
17 September 2020
In a new study, published in the journal Science Translational Medicine, researchers from Queen Mary University of London have developed a prototype drug that can heal cartilage and simultaneously help with pain. In this research Q&A Dr Anne-Sophie Thorup from the Centre for Experimental Medicine and Rheumatology explains why the findings are significant.
A trial led by Queen Mary University of London and Barts Health researchers looking at the effect of stem cell therapy in treating heart attack patients has revealed the importance of specialist centres to extending life.
A newly discovered molecule has been found to provide long-lasting regeneration of bone and cartilage defects, as well as symptom relief, and could potentially play a role in treating osteoarthritis, according to early research in animals led by Queen Mary University of London.
Differences in the shape and texture of men and women’s hearts could potentially explain why their risk of heart disease differs, according to research led by Queen Mary University of London.
A new BHF funded study published in Nature Communications provides new insights into the mechanisms of heart failure and identifies potential novel therapeutic targets.
WHRI COVID Diaries - Q&A with Dr Vanessa Lowe
25 August 2020
In this Q&A WHRI researcher Vanessa Lowe shares her experience of helping with COVID-19 testing at the UK Biocentre in Milton Keynes.
The William Harvey Heart Centre is recruiting healthy male volunteers aged 18-45 for a clinical study investigating the potential role of inorganic nitrate (in the form of beetroot juice) on skin inflammation.
A BHF funded study involving researchers from Queen Mary University of London has found that metformin-a cheap drug commonly used to treat type 2 diabetes- could be used to stop blood vessels from leaking and reverse the damage caused during sepsis and multi-organ failure.
The BSc Pharmacology & Innovative Therapeutics degree programme led by Dr Sadani Cooray at the William Harvey Research Institute at Barts and the London School of Medicine and Dentistry has topped the national leader board for student satisfaction for Pharmacology in the 2020 National Student Survey (NSS).
The British Heart Foundation (BHF) has allowed and encouraged institutions that hold Accelerator Awards (AA) to allocate currently uncommitted funds from their award to supporting Covid-19 research, at the discretion of the award director.
The first virtual William Harvey Annual review took place on Wednesday 24th June 2020 on Microsoft Teams. The programme included the John Vane Award Lecture, selected talks from WHRI researchers and online poster sessions.
Higher rates of severe COVID-19 infections in Black, Asian and Minority Ethnic (BAME) populations are not explained by socioeconomic by socioeconomic or behavioral factors, cardiovascular disease risk, or by vitamin D status, according to new research led by Queen Mary University of London.
Dr Sadani Cooray and Professor Nick Goulding from Queen Mary University of London have been jointly awarded the Rang Prize 2020 by the British Pharmacological Society.
Controlling dopamine signalling by targeting the histamine receptor has been shown to be a promising strategy for preventing the progression of Huntingdon's disease in mice.
Hundreds of new links have been found between people's DNA and the heart's electrical activity, according to a study of almost 300,000 people led by researchers at Queen Mary University of London and the Broad Institute of MIT and Harvard.
In a new study published in the Journal of Clinical Endocrinology & Metabolism researchers investigate whether genetically determined variation in normal-range thyroid function is causally associated with the risk of stroke and Coronary Artery Disease, and then interrogated via which pathways any confirmed relations may be mediated.
Thirty-eight new gene regions that influence the Tpe interval, an electrocardiographic marker associated with susceptibility to malignant ventricular arrhythmias and sudden cardiac death, have been discovered in the largest genetic study to date.
A joint international study led by researchers at QMUL explores how variants that might be overlooked in standard analyses can be pathogenic when combined with much rarer disruptive changes.
Dr Deepti Gurdasani from Queen Mary’s William Harvey Research Institute and Hisham Ziauddeen from University of Cambridge are co-authors of a correspondence piece in The Lancet Global Health which suggests there were limitations in some assumptions used in the COVID-19 pandemic models forming part of the scientific evidence considered by the UK Government. In this blog post, they explain the importance of real-world evidence being used alongside modelling to develop public health responses.
New research from Queen Mary University of London suggests that a novel magnetism-based drug delivery approach could help ensure drugs are not removed from where they are needed in the body.
Queen Mary University of London has been providing support to the UK Lighthouse Labs Network – the national COVID-19 diagnostic lab network. As well as donating a number of laboratory machines, a team of research staff have been seconded to help test thousands of samples from NHS workers every day.
Dr Neil Dufton, Lecturer in Inflammatory Sciences at Queen Mary’s William Harvey Research Institute, has been volunteering at one of the Lighthouse Labs in Milton Keynes and shares his experiences in this blog post.
Antibodies could provide new treatment for OCD
21 April 2020
Mental health conditions such as obsessive compulsive disorder could be treated in a new way using drugs that target the immune system, research suggests.
Queen Mary University of London and Barts Health NHS Trust, as part of their Barts Life Sciences initiative, have begun a new programme of Covid-19 research across Barts Health hospitals, including NHS Nightingale Hospital London.
Charles Knight, Professor of Cardiology at Queen Mary University of London and Consultant Cardiologist at Barts Health NHS Trust, has been announced as the Chief Executive of the new NHS Nightingale Hospital London.
QMUL hosts Precision Medicine Leadership event showcasing developments from academia and industry
8 April 2020
On 5th March 2020, Queen Mary University of London hosted a successful Precision Medicine Leadership event at St Bartholomew’s Great Hall. The event, run in partnership with One Nucleus & Cerba Research, explored new developments in the field of Precision Medicine as well as opportunities for academic/industrial collaboration.
In a new joint study, published in Nature Immunology, researchers have found that ‘aged’ T cells are not a defective end-stage population but are reprogrammed to recognize and kill NK receptors, a process regulated by sestrins.
Diabetes drug reduces complications of long-term steroid therapy
26 February 2020
A drug used to treat type 2 diabetes could offer a simple and cheap solution to reduce dangerous side effects of steroid treatment, new research from Queen Mary University of London suggests.
World first in AI helps predict heart attacks and stroke
14 February 2020
Artificial intelligence has been used for the first time to instantly and accurately measure blood flow, in a new study involving researchers from Queen Mary University of London.
Researchers have identified a new protein linked to age-related macular degeneration (AMD) that could offer new hope for the diagnosis and treatment of the disease, which affects over 1.5 million people in the UK alone.
In a new study, published in the journal Nature Communications, researchers from Barts and The London School of Medicine and Dentistry at Queen Mary University of London observe that the promotion of synovial fibroblast senescence activates tissue protective mechanisms in the arthritic joint.
Professor Márta Korbonits from the William Harvey Research Institute at Queen Mary University of London has been elected to the Hungarian Academy of Medical Sciences.
Pinpointing rare disease mutations
31 January 2020
A new study from Queen Mary University of London and EMBL's European Bioinformatics Institute has uncovered the genes essential for supporting life, which could help researchers to identify mutations responsible for rare childhood diseases.
Regular cannabis use could affect the structure and function of the heart, research led by Queen Mary University of London suggests.
We are pleased to announce that Dr Parjam Zolfaghari, Professor Nick Goulding and Dr Martin Carrier from Queen Mary’s William Harvey Research Institute (WHRI) were one of several winners at the Queen Mary Education Excellence Award and President and Principal's Prizes for 2019/20.
The debate about the potential for exploiting omega-3 fatty acids to improve health has raged for years.
The William Harvey Research Institute is proud to announce that Panos Deloukas, Professor of Cardiovascular Genomics, has been named in the top 0.1% of the world’s most influential researchers.
Professor Charles Hinds recognised for his exceptional contribution to intensive care medicine.